Chiugray, you may be right, but I just don't understand how the shorts would have an out with good news, if their short positions are growing, the short squeeze that will result from UK approval and other positive news will just increase the losses they'll incur. I know some may not believe that an approval is possible, I just believe that the handwriting is pretty clear on the wall that it will be approved. Shorts ought to be moving to the long side, and if it's the MM's themselves who're short, and they probably are, they'll suffer major losses, but not face the same kind of calls that individual shorts do.
To me, the upside potential is unlimited, the most you can lose on the downside is less than 50 cents a share currently. Frankly with what we know about using DCVax-L with Poly-ICLC and/or Keytruda, if we had a total failure in attempting approval without it, I believe the company would be worth far more than it's trading for today by a BP who'd take it into pivotal clinical trials with these combinations. I don't believe this will happen, but worst case it should be worth more than it is now if forced into a buyout scenario because they can't raise the funds needed to do these trials themselves.
I suspect a partnership can come at practically any time after UK approval, but it will depend on how the partnership is to be structured. I don't believe the company will sell more than a small share percentage in such a partnership at under double digit prices. A major partner, someone gaining say 20% or more of the company will require a share price much higher based on what LP's been quoted to say about it. I believe that was before I ever bought shares, but I believe it's still the case.
Gary
